Navigation Links
Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
Date:8/14/2012

s, cancer and potentially other therapeutic areas of interest to AstraZeneca."

"Regulus is pleased to form another significant strategic alliance on microRNA therapeutics," said Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus Therapeutics Inc. "AstraZeneca is a global, innovation-driven company that we believe can greatly aid our efforts to advance microRNA therapeutics to the clinic and the market. The entire field of RNA therapeutics has been rapidly advancing, reaching significant milestones recently. We are committed to realize the broad utility of these new RNA-based medicines to treat human disease in the future. "

Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus Therapeutics Inc., added, "We wanted to partner our microRNA-33 program with AstraZeneca due to their excellent track record on developing and commercializing drugs in cardiovascular and metabolic diseases and their commitment to the RNA therapeutic field.  We look forward to growing our strategic relationship with AstraZeneca with additional targets to develop important first-in-class medicines."

About microRNA-33 for Atherosclerosis

Atherosclerosis is the build-up of plaque that occurs when cholesterol and inflammatory cells accumulate in blood vessels. These plaques can rupture, leading to slowing or blockage of blood flow and ultimately resulting in a heart attack or stroke. Scientific research has shown a strong correlation between high cholesterol levels and cardiovascular disease which, according to the Centers for Disease Control, is the leading cause of death in the United States.

Regulus' lead program for atherosclerosis targets microRNA-33, which has a unique mechanism of action for the management of cholesterol levels. The inhibition of microRNA-33 with our anti-miRs promotes reverse cholesterol transport, or RCT, which is the efflux of cholesterol from specific cholesterol-laden inflammatory cells calle
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nile Therapeutics Reports 2012 Second Quarter Financial Results
2. Zenobia Therapeutics Announce A Partnership With The Alzheimers Drug Discovery Foundation
3. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
4. Echo Therapeutics Announces Second Quarter 2012 Financial Results
5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
6. Echo Therapeutics Announces $20 Million Financing with Platinum-Montaur Life Sciences
7. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
8. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
9. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
10. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
11. Silence Therapeutics - Admission of Shares and Board Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... YORK, July 4, 2011 ... market research report is available ... Global Pharmaceutical Industry Outlook ... Trends and Opportunities, Buyer Spend ...
... 2011 Simulated Environment Concepts (SMEV.PK), the manufacturer ... equipment, announced today that the Company has entered into what ... Management expects that much of the difficult items ... believes it is much more knowledgeable today about the auditing ...
Cached Medicine Technology:Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 2Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 3Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 4Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 5Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 6Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 7Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 8Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 9Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 10Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 11Simulated Environment Concepts Nears Audit Completion 2Simulated Environment Concepts Nears Audit Completion 3
(Date:4/14/2014)... Significant advances have been made in chemotherapy over the ... avoiding healthy tissues continues to be a major challenge. ... drug delivery, including the use of nanocarriers, or capsules, ... locations in the body. , The catch? These carriers ...
(Date:4/14/2014)... at Henry Ford Hospital reached a medical milestone April ... a novel way to access the heart. , Henry ... performing the unique procedure called transcaval valve replacement, which ... , Northern Michigan resident Viola Waller, 80, underwent Henry ...
(Date:4/14/2014)... , , Penicillin, one of the scientific marvels of the ... it once won against bacterial infections. But scientists at ... new approach to restoring its combat effectiveness, even against ... the power of the penicillin family of drugs since ...
(Date:4/14/2014)... their radiation treatment decisions leaves cancer patients feeling more ... distress around the experience, researchers from the Perelman ... report in the journal Cancer . , In ... Neha Vapiwala, MD , an associate professor in the ...
(Date:4/14/2014)... 2014 Popular web information on colorectal cancer is ... doesn,t address the appropriate risks to and concerns of ... suggests. , In a review of a dozen popular ... colorectal cancer screening were written beyond the recommended sixth-grade ...
Breaking Medicine News(10 mins):Health News:Nano shake-up 2Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3
... THURSDAY, Nov. 5 (HealthDay News) -- A program called ... says a U.S. government report. , Over three years, ... percent decrease in the number of students involved in ... report. The number of students who reported experiencing or ...
... adults, producing mild-to-moderate illness , THURSDAY, Nov. 5 (HealthDay ... the predominant flu strain worldwide, although it shows no ... mild-to-moderate symptoms in most people, the World Health Organization,s ... swine flu accounts for up to 70 percent of ...
... ... , ... Now there are some five-star reasons for Houston-area Medicare beneficiaries to choose KelseyCare ... its annual Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey, and KelseyCare Advantage ...
... 5 Attorneys from Dallas, Rasansky Law Firm ... on behalf of the mother of a 2-year-old girl who choked ... ago. The lawsuit includes claims that the day care,s owners quickly ... child,s death from showing up on a state licensing database. , ...
... , FAIRFIELD, Calif., Nov. 5 ChemSW is pleased ... The only Internet site that offers quick, confidential ... listed ChemSW as the top rated vendor overall in ... Despite an overall gloomy report where the customer satisfaction ...
... Nov. 5 Quantros, Inc., an industry leader in ... of care data surveillance solutions, today announced the acquisition ... a publicly traded company spun off from Cardinal Health ... not disclosed. , This latest addition to the ...
Cached Medicine News:Health News:School Violence Drops With Federal Program 2Health News:Swine Flu Virus Dominant Strain Worldwide: WHO 2Health News:Swine Flu Virus Dominant Strain Worldwide: WHO 3Health News:Local Medicare Advantage Plan Gets Five-Star Ratings from Medicare 2Health News:Local Medicare Advantage Plan Gets Five-Star Ratings from Medicare 3Health News:The Rasansky Law Firm Announces Dallas Day Care Death Lawsuit; State Investigation Finds Evidence of Negligence at Woodbridge Day School 2Health News:ChemSW Rated Top Vendor Overall for Customer Satisfaction in Q3 2009 by VendorRate 2Health News:Quantros Acquires MediQual(TM) From CareFusion Corporation 2Health News:Quantros Acquires MediQual(TM) From CareFusion Corporation 3
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
Proven and Efficient Stand-Alone Device. Offers a choice between alternate breath and every breath delivery. This model provides alternate breath delivery....
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
Medicine Products: